Antiretroviral Therapy and the Lipodystrophy Syndrome
- 1 January 2001
- journal article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 6 (1) , 9-20
- https://doi.org/10.1177/135965350100600102
Abstract
‘Lipodystrophy syndrome’ in the setting of HIV infection has come to encompass a collection of morphological and metabolic abnormalities linked with the use of antiretroviral therapy and other risk factors. We review the clinical literature on this subject as it has evolved historically, taking pertinent methodological issues into account.Keywords
This publication has 71 references indexed in Scilit:
- Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and LipodystrophyClinical Infectious Diseases, 2001
- Preliminary Guidelines for the Evaluation and Management of Dyslipidemia in Adults Infected with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus GroupClinical Infectious Diseases, 2000
- Effect of short-course of antiretroviral agents on serum triglycerides of healthy individualsAIDS, 2000
- Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment?AIDS, 1999
- Fat accumulation and HIV-1 protease inhibitorsThe Lancet, 1998
- Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients?AIDS, 1998
- Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalitiesThe Lancet, 1998
- Pseudo‐Cushing's Syndrome in Human Immunodeficiency Virus– Infected PatientsClinical Infectious Diseases, 1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- Changes in AIDS incidence for men who have sex with men, United States 1990–1995AIDS, 1997